SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: lrb who wrote (245)1/29/1998 8:28:00 PM
From: Cacaito  Respond to of 1494
 
Good news, and the type II is ongoing. I will look for the January, Annals of Oncology. There is probably a good commentator besides the article itself.



To: lrb who wrote (245)1/29/1998 8:40:00 PM
From: Peter Silsbee  Read Replies (1) | Respond to of 1494
 
Point taken (re:safety profile)... and nobody was expecting proven efficacy from a Phase I/II trial. But still, "suggestion of potential" really isn't much. The results of the 90-patient trial will be much more convincing, one way or the other.

May the potential be realized.

PLS

Think there'll be another release tomorrow?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News